Solid Biosciences (NASDAQ: SLDB), a life sciences company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has announced the granting of 81,000 restricted stock units (RSUs) to seven newly hired employees. The RSUs will vest over a four-year period, with 25% vesting annually on each grant date anniversary. The equity awards were granted under the Company's 2024 Inducement Stock Incentive Plan and are contingent upon continued employment through each vesting date. These grants were made as inducement material for employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Solid Biosciences (NASDAQ: SLDB), un'azienda nel settore delle scienze della vita specializzata nello sviluppo di terapie genetiche di precisione per malattie neuromuscolari e cardiache, ha annunciato l'assegnazione di 81.000 unità azionarie vincolate (RSU) a sette nuovi dipendenti. Le RSU matureranno in un periodo di quattro anni, con il 25% che matura ogni anno nell'anniversario della data di assegnazione. I premi azionari sono stati concessi nell'ambito del Piano di Incentivo Azionario per l'Anno 2024 della Società e sono subordinati alla permanenza in servizio fino a ciascuna data di maturazione. Questi premi sono stati concessi come incentivo materiale per l'assunzione, in conformità alla Regola di Quotazione Nasdaq 5635(c)(4).
Solid Biosciences (NASDAQ: SLDB), una compañía de ciencias de la vida enfocada en desarrollar medicamentos genéticos de precisión para enfermedades neuromusculares y cardíacas, ha anunciado la concesión de 81,000 unidades de acciones restringidas (RSUs) a siete empleados recién contratados. Las RSUs se consolidarán durante un período de cuatro años, con un 25% consolidándose anualmente en cada aniversario de la fecha de concesión. Las concesiones de acciones se otorgaron bajo el Plan de Incentivos de Acciones por Inducción 2024 de la Compañía y están condicionadas a la continuidad laboral hasta cada fecha de consolidación. Estas concesiones se realizaron como incentivo material para el empleo conforme a la Regla de Cotización Nasdaq 5635(c)(4).
Solid Biosciences(NASDAQ: SLDB)는 신경근육 및 심장 질환을 위한 정밀 유전자 치료제를 개발하는 생명과학 회사로, 7명의 신입 직원에게 81,000개의 제한 주식 단위(RSU)를 부여했다고 발표했습니다. RSU는 4년 기간에 걸쳐 베스팅되며, 매년 부여일 기념일마다 25%씩 베스팅됩니다. 이 주식 보상은 회사의 2024년 유인 주식 인센티브 플랜에 따라 부여되었으며, 각 베스팅일까지 계속 고용 상태를 유지해야 합니다. 이 부여는 나스닥 상장 규칙 5635(c)(4)에 따라 고용 유인을 위한 중요한 자료로 제공되었습니다.
Solid Biosciences (NASDAQ : SLDB), une entreprise de sciences de la vie spécialisée dans le développement de médicaments génétiques de précision pour les maladies neuromusculaires et cardiaques, a annoncé l'attribution de 81 000 unités d'actions restreintes (RSU) à sept nouveaux employés. Les RSU seront acquises sur une période de quatre ans, avec 25 % acquises chaque année à l'anniversaire de la date d'attribution. Les attributions d'actions ont été effectuées dans le cadre du Plan d'Incitation en Actions 2024 de la Société et sont conditionnées à la poursuite de l'emploi jusqu'à chaque date d'acquisition. Ces attributions ont été faites en tant qu'incitation matérielle à l'emploi conformément à la règle de cotation Nasdaq 5635(c)(4).
Solid Biosciences (NASDAQ: SLDB), ein Life-Sciences-Unternehmen, das sich auf die Entwicklung präziser genetischer Medikamente für neuromuskuläre und kardiale Erkrankungen spezialisiert hat, hat die Gewährung von 81.000 Restricted Stock Units (RSUs) an sieben neu eingestellte Mitarbeiter bekannt gegeben. Die RSUs werden über einen Zeitraum von vier Jahren vesten, wobei jeweils 25 % jährlich am Jahrestag des Zuteilungsdatums vesten. Die Aktienzuteilungen erfolgten im Rahmen des 2024 Inducement Stock Incentive Plans des Unternehmens und sind an eine fortlaufende Beschäftigung bis zu den jeweiligen Vesting-Terminen gebunden. Diese Zuteilungen wurden als wesentliche Anreize für die Beschäftigung gemäß der Nasdaq-Listing-Regel 5635(c)(4) gewährt.
Positive
None.
Negative
None.
CHARLESTOWN, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 81,000 restricted stock units (“RSUs”) to seven newly hired employees.
The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee’s continued service with the Company through each applicable vesting date.
This grant was made pursuant to the Company’s 2024 Inducement Stock Incentive Plan and was made as an inducement material to the employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
About Solid Biosciences Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy (Duchenne), Friedreich’s ataxia (FA), catecholaminergic polymorphic ventricular tachycardia (CPVT), TNNT2-mediated dilated cardiomyopathy, BAG3-mediated dilated cardiomyopathy, and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact: Nicole Anderson Director, Investor Relations and Corporate Communications Solid Biosciences Inc. investors@solidbio.com
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
